Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

Objective. To assess the efficacy of rituximab (RTX) in SSc. Methods. Fourteen patients with SSc were evaluated. Eight patients were randomized to receive two cycles of RTX at baseline and 24 weeks [each cycle consisted of four weekly RTX infusions (375 mg/m(2))] in addition to standard treatment, w...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Daoussis, Dimitrios, Liossis, Stamatis-Nick C., Tsamandas, Athanassios C., Kalogeropoulou, Christina, Kazantzi, Alexandra, Sirinian, Chaido, Karampetsou, Maria, Yiannopoulos, Georgios, Andonopoulos, Andrew P.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2010
Ämnen:
Clinical Science
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2806066/
https://ncbi.nlm.nih.gov/pubmed/19447770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/kep093
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk